Michael J Ellis, Christiana Lekka, Katie L Holden, Hanna Tulmin, Faheem Seedat, Darragh P O'Brien, Shalinee Dhayal, Marie-Louise Zeissler, Jakob G Knudsen, Benedikt M Kessler, Noel G Morgan, John A Todd, Sarah J Richardson, M Irina Stefana
Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry
Acta neuropathologica
extracellular signalregulated kinase erkmapk pathway brain hypothesized critical convergent node development autism spectrum disorder reasoned selectively targeting pathway could reverse core autismlike phenotype animal models tested clinically relevant selective inhibitor erk pathway pd325901 mirdametinib mouse model idiopathic autism btbr mice report treating juvenile mice pd325901 reduced erk pathway activation dose durationdependently reduced core diseasemodeling deficits sociability vocalization repetitive behavior reversed abnormal eeg signals analysis revealed subchronic treatment affect weight gain locomotion neuronal density brain parallel treatment c57bl6j mice alter phenotype data indicate selectively inhibiting erk pathway using pd325901 beneficial btbr model thus support notion erk pathway critically involved pathophysiology autism results suggest similar approach could applied animal models syndromic autism dysregulated erk signaling test selectively targeting erk pathway new approach treating autism beenwork supported alberta childrens hospital research foundation jmr nc university calgary faculty veterinary medicine nc kids brain health network nc natural sciences engineering research council canada nc